Finance

Beta
Lists
225430:KOSDAQ
KMPharmaceutical Co Ltd
₩2,155.00
+0.23%
(+5.00) 1D
Jun 10, 3:06:00 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 225430...
Open
₩2,210
High
₩2,590
Low
₩2,150
Mkt. cap
12.02B
Avg. vol.
277.68K
Volume
521.22K
52-wk high
₩6,850
52-wk low
₩517
EPS
-₩713
Shares outstanding
5.58M
No. of employees
63
Open
₩2,210
High
₩2,590
Low
₩2,150
Mkt. cap
12.02B
Avg. vol.
277.68K
Volume
521.22K
52-wk high
₩6,850
52-wk low
₩517
EPS
-₩713
Shares outstanding
5.58M
No. of employees
63
News stories
From sources across the web
About KMPharmaceutical Co Ltd
CEO-
Employees63
Founded2001
Headquarters-
SectorPersonal care products
Websitekmkmp.com
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
3.24B
4.38B
4.29B
4.47B
Cost of goods sold
2.49B
3.03B
3.41B
3.55B
Cost of revenue
2.49B
3.03B
3.41B
3.55B
Research and development expenses
-
-
270.83M
138.25M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.47B
2.16B
1.72B
1.29B
Operating expense
1.47B
2.16B
1.93B
1.76B
Total operating expenses
3.96B
5.19B
5.33B
5.30B
Operating income
-720.67M
-809.28M
-1.04B
-835.90M
Other non operating income
-17.36M
-135.33M
47.58M
6.13M
EBT including unusual items
-963.94M
-1.02B
-1.08B
-834.16M
EBT excluding unusual items
-885.12M
-944.61M
-1.43B
-834.16M
Income tax expense
-
-
84.19M
-
Effective tax rate
-
-
-7.79%
-
Other operating expenses
-
-
15.24M
14.66M
Net income
-963.94M
-1.02B
-1.16B
-834.16M
Net profit margin
-29.74%
-23.20%
-27.13%
-18.67%
Earnings per share
-
-
-
-
Interest and investment income
-
-
155.60M
242.77M
Interest expense
-147.09M
-
-150.91M
-160.60M
Net interest expenses
-147.09M
-
4.69M
82.18M
Depreciation and amortization charges
-
-
-177.94M
95.74M
EBITDA
-480.14M
-569.43M
-803.59M
-612.30M
Gain or loss from assets sale
-
-
2.00K
-
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more